$PPHM News Peregrine plunges on test data 3:17 p.m. June

New Post Public Reply Private Reply Replies (0) Message Board

Dec 30, 2013 at 2:39 PM

$PPHM News

Peregrine plunges on test data 3:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 2:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 12:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 7:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 10:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 10:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 9:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 5:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 4:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 7:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 7:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid

eregrine 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 10:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 5:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 12:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 1:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 1:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 3:23 p.m. May 21, 2012 - MarketWatch

Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 6:37 a.m. Today - benzinga.com
Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers 10:28 a.m. Dec. 23, 2013 - TheStreet.com
Peregrine Reports In-Line Loss - Analyst Blog 2:10 p.m. Dec. 11, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q2 2014 Results - Earnings Call Transcript 7:20 p.m. Dec. 10, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 5:34 p.m. Dec. 10, 2013 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 6.2% - Tale of the Tape 9:39 a.m. Nov. 22, 2013 - Zacks.com
The Race For A Cure For Cancer 1:44 p.m. Nov. 20, 2013 - Seeking Alpha
Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma 8:10 a.m. Nov. 8, 2013 - benzinga.com
Peregrine Pharmaceuticals is now in Oversold Territory - Tale of the Tape 7:06 a.m. Nov. 8, 2013 - Zacks.com
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals' CEO Hosts Annual Meeting of Stockholders (Transcript) 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Peregrine Pharmaceuticals, Inc. - Shareholder/Analyst Call 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Biotech: Let's Make A Billion-Dollar Deal, Part 2 2:00 p.m. Oct. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals Earnings: Here’s Why Investors are Not Excited Now 8:58 a.m. Sept. 10, 2013 - Wall St. Cheat Sheet
Peregrine Reports In-Line Loss - Analyst Blog 8:30 a.m. Sept. 10, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q1 2014 Results - Earnings Call Transcript 6:10 p.m. Sept. 9, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 3:24 p.m. Sept. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
Encouraging News for Peregrine Pharma - Analyst Blog 4:15 p.m. Aug. 20, 2013 - Zacks.com
9 Compelling Reasons To Buy Opexa Therapeutics Right Now 11:44 a.m. Aug. 15, 2013 - Seeking Alpha
Peregrine Pharmaceuticals: Good Looking, But Still Single 9:27 a.m. July 23, 2013 - Seeking Alpha

Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 7:31 a.m. Today - Marketwire
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments 4:00 p.m. Dec. 10, 2013 - Marketwire
Peregrine Pharmaceuticals Announces Upcoming Events 4:00 p.m. Nov. 26, 2013 - Marketwire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
OXBT, HZNP, PPHM and NWBO added to NASDAQ Healthcare Stock Watch List at GSR 10:35 a.m. Nov. 11, 2013 - ACCESSWIRE
Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies 9:01 a.m. Nov. 8, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference 4:00 p.m. Nov. 5, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 3:03 p.m. Oct. 31, 2013 - PR Newswire
Symposium at IALSC World Conference on Lung Cancer to Highlight Novel Immune Checkpoints Including Peregrine Pharmaceuticals' Bavituximab PS Target 7:31 a.m. Oct. 15, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 10:25 a.m. Oct. 9, 2013 - PR Newswire
Record Use of At-the-Market (ATM) Offerings by U.S. Life Sciences Companies in First Half of 2013, Reports Brinson Patrick 7:00 a.m. Sept. 17, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2014 Financial Results and Recent Developments 3:00 p.m. Sept. 9, 2013 - Marketwire
Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research 7:31 a.m. Sept. 9, 2013 - Marketwire
Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc. 4:11 p.m. Sept. 6, 2013 - PR Newswire
Peregrine to Report First Quarter Fiscal Year 2014 Financial Results After Market Close on September 9, 2013 3:06 p.m. Sept. 3, 2013 - Marketwire
Bavituximab's Mechanism of Action Highlighted at Immunomodulatory Therapeutic Antibodies for Cancer Conference 2:01 p.m. Aug. 14, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Upcoming Conferences 3:00 p.m. Aug. 6, 2013 - Marketwire
Morning Research: Celgene, Edwards Lifesciences, Forest Laboratories, and Peregrine Pharma 8:12 a.m. July 31, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Recent Developments 3:06 p.m. July 11, 2013 - Marketwire
Positive Clinical Data, Marketing Authorizations, and New Appointments Support Growth in Biotech Companies - Research Report on Santarus, VIVUS, Epizyme, Peregrine Pharmaceuticals, and PDL BioPharma 7:00 a.m. July 3, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ACEMAGIC Unveils New AI Mini Workstation at IFA 2026

A Glimpse Into ACEMAGIC's Latest Innovation Look if you had told me five years ago that AI mini workstations would be making waves, I'd have probably smirked. Yet, here we are; ACEMAGIC is setting the stage at IFA 2026 in Berlin with their fresh-out-the-oven F9A AI mini workstation, powered by AMD's Ryzen AI Max+ PRO 495 processor. It all goes down from September 4 to 8...

SimpliTrain's Momentum in LMS Market Heating Up

SimpliTrain Finds its Groove in the LMS Arena Out here in Delray Beach, SimpliTrain's making waves in the Learning Management System (LMS) market, recently snagging the 'Pervasive Player' tag from MarketsandMarkets' 360Quadrants platform. This cloud-based learning powerhouse ain't just playing around; they're doubling down with expansion into AI and other fancy tech bits...

LIV Golf's Big Play: Restructuring with Saudi PIF

Trailblazing Change in the Golf World It's like watching a high-stakes game of chess where pieces are worth billions. White Knight Capital Corp. has thrown its hat into the ring with the Public Investment Fund of Saudi Arabia to overhaul LIV Golf Enterprises. This isn't your average Monday morning golf chat; it's full-on corporate drama with financial steroids. Debt Swap...

UGREEN's MagFlow Series: A Game-Changer in Charging

UGREEN Unveils a Cool Revolution in Charging Out in Foxborough, UGREEN is shaking things up at its Smart Living Launch Event. The big reveal? The MagFlow Series, their flagship wireless charging lineup, which promises faster and cooler charging than ever before. UGREEN's taking wireless charging to new heights, and that's got my attention. What Makes MagFlow Stand Out...

Beauty Industry's $56B Boom: Trends and Innovations

A Whopping $56 Billion Beauty Surge U.S. beauty sales have jumped by 7%, translating into a dizzying $56 billion 'feel-good effect' in the industry. People are shelling out for products that make them look and feel their best. This isn't just about vanity—consumers are investing in self-care and wellness, a trend shaping what we see on the vanity counter. Every spritz...

Lupin Gains FDA Nod for Modafinil, Eyes US Market

In the ever-evolving landscape of pharmaceuticals, Lupin Limited's recent triumph snagging FDA approval for their Modafinil Tablets was a move you couldn't miss even if you'd tried. While the rooms of Mumbai and boardrooms around the globe might have been abuzz, investors should tune in to the humming potential of this development—especially if they're navigating the...

Graywind Redefines Flexibility with New Blinds 2.0

Sliding blinds—who knew they'd stir up such a fuss? But here comes Graywind, rolling out their Manual Sliding Track Blinds 2.0, and it's clear they're turning heads in Santa Clara and beyond. This ain't your grandma's drapery setup. We're talking about a sleek, mid-to-premium panel-track system designed to cater to modern living spaces and architectural whimsy. It's...

Halloween 2026: Gemmy's Animatronics Add Thrills

Halloween's New Twist with Gemmy's Animatronics Well, just when you thought Halloween couldn't get any more over the top, here comes Gemmy with their 3-foot tall animatronic characters ready to give your trick-or-treat scene that extra jolt. These aren't just any run-of-the-mill decorations. Nope, they come with a twist—an industrial-strength twist of scares and sweets...

Megan Holdings Investors Face Deadline for Class Action

Forgive my bluntness, but if you've been snoozing on your Megan Holdings Limited (NASDAQ:MGN) shares, it's time to wake up and smell the lawsuit papers. They're flying around faster than news at a market crash. If you snagged those shares between September 26, 2025, and March 25, 2026, or got in during the IPO on September 26, 2025, here's the deal: the deadline looms on...

Cheetah Mobile Q2 2026 Results: What's on the Horizon?

Anticipation Builds for Cheetah Mobile's Q2 Results Nine rounds into the slugfest that is the 2026 market, we've got another round approaching—Cheetah Mobile is set to unveil its second quarter numbers on September 11th. This isn't some sleepy, run-of-the-mill report either; NYSE:CMCM is a player with skin in the IT game, and commentators are eyeing the clock with...